Case Report
A rare cause of Cushing’s syndrome demonstrates analytical discrepancies between the Roche E170 and Bayer Centaur testosterone assays
Sian Hancock1, Rachel A Still1, Andrew M Fielding1, John F Doran1 and Jeffrey W Stephens2
1Chemical Pathology Services; 2Department of Medicine, Swansea NHS Trust, Morriston Hospital, Swansea SA6 6NL, UK Corresponding author: Dr Sian Hancock. Email: sian.hancock@swansea-tr.wales.nhs.uk
Abstract
The initial biochemical investigations of a female patient with suspected Cushing’s syndrome revealed abnormal endocrine results, including a marked elevation of serum testosterone. Overnight and low-dose dexamethasone suppression tests confirmed the diagnosis of Cushing’s syndrome. Imaging investigations revealed an appearance compatible with adrenocortical carcinoma with metastases in the lungs and liver. This tumour is a rare cause of Cushing’s syndrome. Two different automated testosterone immunoassays were used during the investigation of this patient, and analytical discrepancies in the patient’s testosterone results were found. The two assays used, as well as potential causes of the difference in results will be discussed.
Ann Clin Biochem 2008; 45: 328-330. DOI: 10.1258/acb.2007.007166
Case history
A 40-year-old female patient with diabetes mellitus was admitted to hospital feeling weak and lethargic with erratic glycaemic control and intermittent blurred vision. The patient had a five-year history of hypertension and had been diagnosed with type 2 diabetes five months pre- viously. On examination, the patient was noted to have Cushingoid features and she was referred to an endocrinol- ogist for further investigation. Due to her suboptimal gly- caemic and hypertensive control since diagnosis she was also referred to the local diabetes centre. The patient was on a range of medication including gliclazide (160 mg b.i.d. [twice daily]), metformin (1 g b.i.d.), valsartan (80 mg b.i.d.), atenolol (50 mg o.d. [once daily]), Natrilix MR (1.5 mg o.d.) and amlodipine (5 mg o.d.).
On further examination the patient was found to have a plethoric round face, telangiectasia, excess hair growth in a beard distribution and over the back, central adiposity with peripheral wasting of muscle, purple striae over the abdomen and a buffalo hump. She had a body mass index of 29 and an elevated blood pressure of 150/99. An abdominal examination revealed a 3 cm hepatomegaly. The patient had a 2-3-year history of redness over the cheeks, and over the previous six months she had experi- enced increasing lethargy and difficulty getting up from a chair. The patient’s husband noted that she had a short temper, poor attention, mood swings and increasing weight for the previous 12 months.
Serum urea and electrolytes were normal with liver func- tion tests showing slightly elevated alanine transferase (ALT) (48 U/L; reference range 0-31 U/L) and an elevated y-glutamyltransferase (GGT) (191 U/L; reference range <64 U/L). Endocrine investigations revealed an elevated serum cortisol (895 nmol/L) on a mid-day sample and a markedly elevated testosterone (18.8 nmol/L; reference range 0-3 nmol/L). The high serum testosterone result with a low sex hormone binding globulin (SHBG) (10 nmol/L, reference range 20-120 nmol/L) gave rise to an abnormal testosterone:SHBG ratio (1.88; reference range 0-0.05). Thyroid function tests, prolactin, oestradiol and gonadotrophins were normal. An overnight (1 mg) dexa- methasone suppression test was performed, which failed to suppress the serum cortisol (09:00 h cortisol 863 nmol/ L). A two-day low-dose dexamethasone suppression test was subsequently performed, which also failed to suppress the serum cortisol (09:00 h cortisol 839 nmol/L).
A computerized tomography (CT) scan of the abdomen, pelvis and chest revealed a large 8 x 6 cm irregular mass arising from the left adrenal gland, along with focal mass lesions throughout both lobes of the liver and both lungs. The rounded pulmonary lesions were of varying sizes ranging from a few mm to over 1 cm in size with an increased number at the bases of the lungs, indicative of metastases. A working diagnosis of adrenocortical carci- noma with liver and lung metastases was made, which was confirmed following an ultrasound guided biopsy of
the liver lesions. Appearance of the liver tissue was in keeping with metastatic adrenocortical carcinoma and the immunohistochemical analysis confirmed the diagnosis. Tumour cells were inhibin positive and were negative for Cam 5.2, AE1/AE3 (for renal cell carcinoma) and hepato- cyte markers.
Additional biochemical investigations revealed 24h urinary metadrenaline and normetadrenaline within the reference ranges. Serum adrenocorticotrophic hormone (ACTH) was suppressed (<5 ng/L, reference range for 09:00 h sample 7-51 ng/L), whilst urine free cortisol (1163 nmol/24 h, reference range < 300 nmol/24 h) and serum dehydroepiandrosterone sulphate (DHEA-S) (> 27 µmol/L, reference range 1.7-9.2 umol/L) were elevated.
Due to the large size of the adrenal tumour and the extent of the metastases, surgery was not a curative option, and medical therapies were commenced. The patient was treated with metyrapone (1 g q.d.s. [four times daily]) and dexamethasone (0.5 mg b.i.d.) as a block and replace regimen, in an attempt to relieve the symptoms attributed to cortisol excess. Two months following diagnosis the patient developed leg weakness and pain which resulted in difficulty mobilizing. A bone and magnetic resonance imaging (MRI) scan revealed metastases to the lumbar spine, pelvis and femoral heads. A subsequent fracture to the left neck of femur was treated with a total hip replace- ment four months after initial diagnosis. The patient is cur- rently receiving palliative care in the form of analgesia and radiotherapy for relief of bone pain.
Adrenocortical carcinoma
Adrenocortical carcinoma is a rare malignancy (incidence 1-2 per 1 million population), which presents with adrenal steroid hormone excess in 60% of cases.1 Androgen-secreting adrenal tumours in women induce hirsutism, virilization and oligomenorrhoea, while oestrogen-secreting tumours in men lead to gynaecomastia and testicular atrophy. Presentation exhibits a bimodal age distribution with a peak in childhood and a second higher peak in the fourth and fifth decade.
Tumour staging is dependent on the size of the primary tumour and whether there is local invasion or distant metas- tases. Therapeutic options include surgery, radiation and medical therapy which are tailored according to the severity of disease. At diagnosis, as in this case, most patients have severe disease,2 which leads to the poor prognosis associ- ated with this form of cancer. Diagnosis of stage IV meta- static disease leads to a median survival of less than 12 months.1
Analytical discrepancies in testosterone results
During the investigation of this patient, serum testosterone was analysed locally using a Roche Diagnostics Modular E170 unit. The testosterone concentrations measured on this patient ranged between 15 and 20 nmol/L. Female
testosterone results greater than 3.5 nmol/L are routinely sent to another laboratory (University Hospital of Wales, Cardiff), where they are analysed on the Bayer Centaur prior to and following ether extraction. There was a large difference in testosterone results obtained by the Roche E170 (17 nmol/L) and the Bayer Centaur analyser (8.2 nmol/L prior to and 7.3 nmol/L following ether extrac- tion, respectively). The similarity in the results before and after ether extraction using the Bayer assay implied that there was significant interference with measurement of tes- tosterone in this serum sample using the Roche assay. It is well recognized that ether extraction does not remove all interfering substances,3 and so the Bayer testosterone result itself is not necessarily ‘accurate’. Studies have pre- viously demonstrated that many direct immunoassays including the Roche Elecsys 2010 assay, have a positive bias compared with the reference method for testosterone, i.e. isotope-dilution gas chromatography mass spectrometry (ID-GCMS).4
The Roche and Bayer assays are both competitive immu- noassays using electrochemiluminescence and direct chemi- luminescent technology with comparable measuring ranges of 0.07-52.0 nmol/L and 0.35-52.1 nmol/L, respectively. However, there are marked differences in both the assay architecture and the antibodies used in the two assays. First, the Roche assay employs a biotinylated monoclonal antitestosterone antibody, whereas the Bayer assay uses a polyclonal antitestosterone antibody. Secondly, the assays differ in the timing of the release of testosterone from its binding proteins. The Roche assay involves patient serum, the labelled monoclonal antitestosterone antibody and the competing labelled testosterone being combined in the first step. The labelled testosterone contains the releasing agent which causes displacement of the patient testosterone from its binding proteins. The Bayer assay initially involves the addition of a releasing agent to the patient serum, before any other components of the immunoassay. Generally, monoclonal antibodies are regarded as more specific but in this case it was the Roche monoclonal assay that was sus- ceptible to interference. It is speculated that the different assay architecture and possibly the different affinities and avidities of the antibodies used in the two assays contribute to the Roche assay being more susceptible to interference.
The differences in the stated cross-reactivities of the two assays are provided in Table 1. The most prominent differ- ence in cross-reactivities is that for 5-a-dihydrotestosterone,
| Compound | Cross-reactivity with testosterone assay (%) | |
|---|---|---|
| Roche E170 assay | Bayer Centaur assay | |
| Androstenedione | 0.91% | 0.94% |
| Danazol | Not detected | <0.1% |
| Dehydroepiandrosterone sulphate | 0.01% | <0.1% |
| Oestradiol | Not detected | 0.02% |
| 5-a-dihydrotestosterone | 1.89% | 5.4% |
where cross reactivity for the Bayer assay is approximately three-fold greater than that for the Roche assay. However, the relative serum concentrations of testosterone and 5-a-dihydrotestosterone would make this cross-reactivity clinically insignificant.
Despite the stated low cross-reactivities of the Roche E170 testosterone assay with other steroid hormones, the fact that some of these steroid hormones are normally found in the serum in markedly higher concentrations than testosterone may contribute to analytical interference. The stated cross- reactivity of the Roche testosterone assay with DHEA-S is low at 0.01%. However, 1000 nmol/L of DHEA-S equates to 0.1 nmol/L of ‘pseudo’ testosterone (Roche correspon- dence), and therefore 10,000 nmol/L of DHEA-S (i.e. 10 µmol/L) equates to 1 nmol/L of ‘pseudo’ testosterone. The upper limit of the quoted female DHEA-S reference range is 9.2 umol/L, which means that it may normally con- tribute up to 0.9 nmol/L of ‘pseudo’ testosterone. In this case report the patient had an initial DHEA-S concentration of greater than 27 umol/L (the upper limit of the analytical range). The exact concentration was not elucidated by dilution. If DHEA-S was solely responsible for the interfer- ence in the Roche assay, the 10 nmol/L difference in measured testosterone between the Roche and Bayer assays could have resulted from of a DHEA-S concentration in the region of 100 umol/L. The Bayer testosterone results prior to and following ether extraction indicate that the high concentrations of DHEA-S in this patient’s serum appeared not to have caused a problem in the Bayer assay.
This degree of cross-reactivity in the Roche assay could potentially be clinically misleading. DHEA-S within the reference range in a female patient’s serum could contribute ‘pseudo’ testosterone and shift the patient’s testosterone result above the reference range. This could potentially lead to further laboratory investigations, including ether extractions, or clinical investigations where malignancy may be wrongly suspected. In this case, the falsely elevated testosterone results did not lead to any harm to the patient. Both the Bayer and Roche testosterone results were in the region where malignancy would be suspected in a female patient. The cross-reactivity of DHEA-S in the Roche testos- terone assay makes this assay unsuitable for investigation of patients with suspected adrenal carcinomas, where the DHEA-S is usually elevated.5
The exact cause of interference in the Roche assay in this case report has not been experimentally proven, and it is only postulated that DHEA-S is the cause of the interfer- ence. Interference from endogenous steroid hormones as well as exogenous sources is a well-recognized problem associated with automated direct immunoassays for testos- terone. Recently, it has been reported that significant
cross-reactivity with DHEA-S was the cause of interference in the Abbott Architect assay.6 In addition, the Roche Elecsys, Roche E170 Modular and Beckman Access/DxI assays have been shown to be susceptible to intereference to a similar extent, whilst minimal effects were observed for the Bayer Advia Centaur.7 Consistent with this finding, the discrepant testosterone results reported in this case were higher when assayed using the Roche Modular E170 assay. Mass spectrometric methods such as ID-GCMS are now considered reference methods for testos- terone measurement, and simpler liquid chromatography - tandem mass spectrometry (LC-MS/MS) methods are becoming routine practice in some clinical laboratories.6 The improved specificity of these methods will lead to more reliable and meaningful testosterone results on female patients. This case illustrates that potentially mis- leading serum testosterone results can be reported.
ACKNOWLEDGEMENTS
Endocrine section staff at Department of Medical Biochemistry and Immunology (University Hospital of Wales, Cardiff) for analysis of solvent extracted serum tes- tosterone, ACTH, DHEA-S and urine free cortisol.
NOTE
The Bayer Centaur analyser is now known as the Siemens Centaur analyser.
REFERENCES
1 Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-37
2 Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-55
3 Kane J, Middle J, Cawood M. Measurement of serum testosterone in women, what should we do? Ann Clin Biochem 2007;44:5-15
4 Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49:1381-95
5 Fassnacht M, Kenn W, Allolio B. Adrenal tumours: how to establish malignancy? J Endocrinol Invest 2004;27:387-99
6 Warner MH, Kane JW, Atkin SL, Kilpatrick ES. Dehydroepiandrosterone sulphate interferes with the Abbott Architect direct immunoassay for testosterone. Ann Clin Biochem 2006;43:196-9
7 Middle JG. Dehydroepiandrostenedione sulphate interferes in many direct immunoassays for testosterone. Ann Clin Biochem 2007;44:173-7
Copyright of Annals of Clinical Biochemistry is the property of Royal Society of Medicine Press Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder’s express written permission. However, users may print, download, or email articles for individual use.